肝素及其类似物抗乳腺癌作用研究进展

Research progress of the relationship between breast cancer and heparin as well as its analogues

肿瘤是深静脉血栓形成的高危因素之一,因而很多肿瘤患者会伴发静脉血栓形成,这使得抗凝治疗必不可少。近期很多临床研究及Meta分析表明,肿瘤患者在接受抗凝治疗后,生存期得到明显改善。肝素是一种广泛应用于静脉血栓的抗凝剂,据此,研究人员提出猜想:肝素是否具有抗肿瘤活性?大量实验性研究就此全面开展,结果证实:普通肝素、低分子肝素、肝素各种化学衍生物与多种肿瘤的发生、发展进程相关。该文主要概述了肝素及其类似物抗乳腺癌的作用及其可能的内在机制。

Tumor is one of the most risk factors for deep venous thrombosis. So many patients with cancer will be associated with venous thrombosis, which makes anticoagulant therapy indispensable. A lot of recent clinical studies and Meta analysis showed that the survival time of tumor patients after anticoagulant therapy had been significantly improved. Heparin is an anticoagulant widely used in venous thromboembolism. Based on this, researchers have speculated that whether heparin has anti-tumor activity. In response to this, a large number of experimental studies were carried out, which confirmed that heparin, low molecular weight heparin, and various chemical derivatives of heparin had been involved in the occurrence and development of multiple tumors. This article mainly outlines the relationship and mechanisms between breast cancer and heparin as well as its analogues.